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Abstract
Objective: Carbapenem-resistant Acinetobacter baumannii (CRAB) has emerged as an important pathogen causing
healthcare-associated infections (HAIs) in Taiwan. The present study is aimed to investigate the epidemiology of HAIs
caused by CRAB and the association of CRAB infection and hospital usage of different antimicrobials.
Methods: Two nationwide databases in the period 2003 to 2008, the Taiwan Nosocomial Infection Surveillance System and
National Health Insurance claim data, were used for analysis. A total of 13,811 healthcare-associated A. baumannii infections
and antimicrobial usage data from 121 hospitals were analyzed.
Results: There was a significant increase in the proportion of number of HAIs caused by CRAB over that by all A. baumannii
(CRABpAB), from 14% in 2003 to 46% in 2008 (P,0.0001). The greatest increase was in central Taiwan, from 4% in 2003 to
62% in 2008 (P,0.0001). Use of anti-pseudomonal carbapenems, but not other classes of antibiotics, was significantly
correlated with the increase of CRABpAB (r=0.86, P,0.0001).
Conclusions: We suggested that dedicated use of anti-pseudomonal carbapenems would be an important intervention to
control the increase of CRABpAB.
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Introduction
Acinetobacter baumannii is an important pathogen causing
healthcare-associated infections (HAIs) [1] and frequently re-
sponsible for outbreaks in healthcare facilities, especially in areas
with hot and humid climate [2]. The spread of A. baumannii
infection is difficult to control because this species can survive for
prolonged periods on environmental surfaces. Infection caused by
A. baumannii is hard to treat since it can acquire resistance to
multiple antimicrobial agents [3]. Imipenem and meropenem
were traditionally the most effective antimicrobials against A.
baumannii [4]. However, carbapenem-resistant A. baumannii
(CRAB) has become common worldwide [5]. In Taiwan,
researchers first identified CRAB in the late 1990s, and reported
a rapid increase in the late 2000s [6]. The major risk factors for
spread of multidrug-resistant organisms (MDROs), including
CRAB, are poor adherence to infection control measures and
overuse of certain antimicrobials [7].
Previous studies demonstrated that prior use of imipenem and
meropenem was an independent risk factor for CRAB infection
and/or colonization [8,9]. However, some researches indicated
that emergence of MDROs in a population was dependent on not
only the direct effect of individual antimicrobial exposure but also
the indirect effect due to increased bacterial resistance in others
[10,11]. This might be because that the higher colonization
pressure by MDROs is, the more likely the transmission of
MDROs to other patients occurs [12,13]. Therefore, antimicrobial
exposures in other patients might also indirectly affect the risk of
acquiring resistant bacteria. Thus, studies that only evaluate
individual exposure to antimicrobial agents may under-estimate
the total effect of antimicrobial use on the acquisition of resistant
bacteria because they do not consider these indirect effects from
the antimicrobial exposures in other patients [10]. Ecological
studies that use aggregated population-level data may be more
suitable for such investigations because they consider the exposure
of an entire population.
The Centers for Disease Control, Taiwan (Taiwan CDC)
developed a web-based surveillance system that collects the
nationwide HAIs data from intensive care units (ICUs) of
participating hospitals and periodically provides feedback to
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overall decrease of HAIs in ICUs of acute care hospitals (medical
centers, from 19.8 in 2003 to 12.1 in 2008 per 1000 patient-days;
regional hospitals, from 14.1 in 2003 to 9.5 in 2008 per 1000
patient-days) [14,15]. During this period, A. baumannii was the
most common causative pathogen of HAI in the ICUs of medical
centers (10%) and regional hospitals (12.2%) [14,15,16]. Although
the overall rate of HAIs decreased, there was an increase in the
proportion of number of HAIs caused by CRAB over that by all A.
baumannii (CRABpAB). In particular, from 2003 to 2008, the
CRABpAB increased in the ICUs of medical centers from 16.4%
to 56.3% and increased in regional hospitals from 18.2% to 62.1%
[14,15]. It is unknown whether this increase of CRABpAB was
associated with the use of certain antimicrobials, but this
information is clearly important for the design of interventions
to control the increase of CRAB. The aims of the present study are
to describe the epidemiological features of HAIs caused by A.
baumannii and to analyze the association of CRAB infection and
hospital usage of different classes of antimicrobial agents.
Methods
Healthcare-associated A. baumannii infections
Data on healthcare-associated A. baumannii infections were
retrieved from the Taiwan Nosocomial Infections Surveillance
system (TNIS) database, which was established in 2002 to collect
information about HAIs at participating hospitals. The purposes of
the TNIS were to help participating hospitals to develop their own
surveillance systems for HAIs and to provide timely recognition of
infection control problems. TNIS hospitals voluntarily report
demographic data of patients with HAIs, the responsible
pathogens for these HAIs, and the antimicrobial susceptibilities
(based on the disk diffusion method) of the responsible pathogens.
During the study period of 2003 to 2008, a total of 121 hospitals
(21 medical centers, 79 regional hospitals, and 21 local hospitals) in
Taiwan voluntarily participated in the TNIS. Medical centers in
Taiwan generally were referred to hospitals with a capacity of
more than 1000 beds and providing tertiary care. Local hospitals
were referred to hospitals with a capacity of less than 500 beds and
providing primary care. Regional hospitals were those with a size
and scale being between the above two types of hospitals. The
definition of HAIs during the study period was according to that
provided by CDC, USA [17]. Biochemistry methods were used to
identify the species of bacterial isolates [18]. Imipenem-resistant or
meropenem-resistant A. baumannii, as determined by the disk
diffusion method described by the Clinical and Laboratory
Standards Institute, was considered as CRAB [19]. For every
episode of these reported HAIs, only one A. baumannii isolate was
enrolled for calculation.
Hospital antimicrobial usage
Data on inpatient antimicrobial usage were obtained from
National Health Insurance (NHI) claim data, which has been
collected by the Bureau of National Health Insurance (BNHI)
since 1995 for reimbursement purposes. In Taiwan, because of the
enforcement of compulsory and universal national health in-
surance, the coverage rate of NHI is 99% in Taiwanese population
and 92% in Taiwanese hospitals [20]. All TNIS hospitals enrolled
in this study were covered by NHI. The NHI database contains
registration files and original claim data for reimbursement. The
BNHI consists of six geographically based branches: Taipei,
North, Central, South, Kaoping, and East. The five classes of
antimicrobial agents analyzed in this study were: anti-pseudomo-
nal cephalosporins (including cefoperazone, ceftazidime, cefepime,
and cefpirome), anti-pseudomonal carbapenems (imipenem/
cilastatin, and meropenem), b-lactam-b-lactamase inhibitor com-
binations with anti-pseudomonal effects (piperacillin/tazobactam,
and ticarcillin/clavulanate), anti-pseudomonal fluoroquinolones
(ciprofloxacin, and levofloxacin), and aminoglycosides (amikacin,
tobramycin, gentamicin, isepamicin, and netilmicin), modified
from suggestion by Paterson [9]. The usage of these antimicrobials
is transformed as the number of defined daily doses (DDD) per
1000 patient-days, based on the ‘anatomical therapeutical
chemical classification/Defined Daily Doses (ATC/DDD) system’
developed by the World Health Organization, [21] and then the
usage of antimicrobials belonging to the same antimicrobial group
were pooled together. Annual data of antimicrobial use by
individual hospitals during the study period (2003–2008) were
used.
Linking data from TNIS and NHI
Each hospital in Taiwan has a unique identification code, and
this was used to link hospital data from the TNIS and NHI
databases. After this process, the identification codes were fully
encrypted to preserve anonymity. To protect the privacy of
hospitals, all personal information was kept confidential. This
study was conducted according to the Declaration of Helsinki and
was approved by the Institutional Review Board (IRB) of Taiwan
CDC. The IRB waived the need for informed consents (both
written and oral) from participants because this was a retrospective
observational study, involved very minimal risk to the subjects, did
not include intentional deception, and did not involve sensitive
populations or topics; this waiver does not adversely affect the
rights and welfare of the subjects.
Table 1. Characteristics of the study hospitals and hospital-
years according to hospital type, study year, and geographic
region.
Demographics
No. (%) of
hospitals (n=121)
No. (%) of
hospital-years
(n=409)
Hospital type
Medical center 16 (13) 74 (18)
Regional hospital 53 (44) 209 (51)
Local hospital 52 (43) 126 (31)
Study year
2003 - 56 (14)
2004 - 56 (14)
2005 - 66 (16)
2006 - 66 (16)
2007 - 77 (19)
2008 - 88 (22)
Geographic region
a
Taipei 30 (25) 105 (26)
North 18 (15) 62 (15)
Central 29 (24) 78 (19)
South 17 (14) 64 (16)
Kaoping 24 (20) 87 (21)
East 3 (2) 13 (3)
aTaiwan was divided into 6 geographic regions: Taipei, North, Central, South,
Kaoping, and East.
doi:10.1371/journal.pone.0037788.t001
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Data of healthcare-associated A. baumannii infections and use of
antimicrobial agents were analyzed annually for each of the six
regions. Central tendency was expressed as the median and
interquartile range (IQR, data between 25
th and 75
th percentiles).
The Chi square test for trend was performed to assess percentages
over time and Poisson regression were used for analyzing
incidence trends of HAI. The epidemiological features associated
with the CRAB infections were assessed by multivariate analysis
using a logistic-regression model. Odds ratios and 95 percent
confidence intervals (CIs) were calculated for the differences
among the characteristics. Correlations (rs) between annual
CRABpAB and hospital antimicrobial usage were assessed using
a repeated-measures mixed-effects model. The East region was
excluded in correlation analysis because it had only three hospitals
with limited A. baumannii isolates, resulting in high variability. P
values less than 0.05 were considered statistically significant. SAS
version 9.2 for Windows (SAS Institute Inc., Cary, NC) was used
for all statistical analysis.
Results
Demographics of study hospitals
Table 1 shows basic demographic data of the 121 study
hospitals. A total of 409 hospital-years were analyzed during the 6-
year study period (2003–2008). The median bed capacities of the
medical centers, regional hospitals, and local hospitals were 1460,
626, and 183, respectively. The median study duration of
participating hospitals was 3 years. The median number of annual
admissions was 15287 (IQR: 9368–24607) in 2003 (56 hospitals in
that year) and 12289 (IQR: 3920–21132) in 2008 (88 hospitals in
that year). The median duration of hospital stays was 10.0 days
(IQR: 8.3–11.2) in 2003 and 10.0 days (IQR: 8.4–13.3) in 2008.
Epidemiological features for CRAB infections
Table 2 shows the basic epidemiological features A. baumannii
HAIs. A total of 6516 of the 13811 infections (47.2%) occurred in
ICUs. The number of HAIs caused by carbapenem-susceptible A.
baumannii (CSAB) decreased over time, but the number of HAIs
caused by CRAB increased over time. Thus, the CRABpAB
increased from 14.1% in 2003 to 46.3% in 2008 (P,0.0001).
Stratification of data by hospital types indicated that the
CRABpAB increased from 13.6% in 2003 to 43.9% in 2008 at
medical centers (P,0.0001), from 15.4% to 49.0% at regional
hospitals (P,0.0001), and from 13.0% to 44.3% at local hospitals
Table 2. Epidemiological characteristics of the 13811 patients with A. baumannii infection.
Variables
No. of susceptible isolates (%)
(n=9,496)
No. of resistant isolates (%)
(n=4,315)
OR
(95% CI)
1
Type of infection
Bloodstream infection 2,683 (77.3) 786 (22.7) 1.0
Surgical site infection 552 (72.5) 209 (27.5) 1.3 (1.1–1.5)
Pneumonia 3,174 (65.6) 1,667 (34.4) 1.8 (1.6–2.0)
Urinary tract infection 2,126 (64.6) 1,165 (35.4) 1.9 (1.7–2.1)
Other 961 (66.3) 488 (33.7) 1.7 (1.5–2.0)
Hospital type
Medical center 5,058(71.9) 1,975(28.1) 1.0
Regional hospital 3,403(64.6) 1,866(35.4) 1.4 (1.3–1.5)
Local hospital 1,035(68.6) 474(31.4) 1.2 (1.0–1.3)
Study year
2003 2,028 (85.9) 334 (14.1) 1.0
2004 1,635 (76.7) 497 (23.3) 1.8 (1.6–2.2)
2005 1,516 (73.7) 540 (26.3) 2.2 (1.9–2.5)
2006 1,300 (70.7) 539 (29.3) 2.5 (2.2–2.9)
2007 1,482 (57.9) 1,079 (42.1) 4.4 (3.8–5.1)
2008 1,535 (53.7) 1,326 (46.3) 5.2 (4.6–6.0)
1Abbreviations: OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0037788.t002
Figure 1. Healthcare-associated infection rate, A. baumannii
infection rate, and CRAB infection rate from 2003 to 2008.
doi:10.1371/journal.pone.0037788.g001
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pAB compared to medical centers (odds ratio [OR]: 1.4; 95%
confident interval [CI]: 1.3–1.5). After controlling the study years
and hospital types, it was found that bloodstream infection was
significantly less likely to be caused by CRAB than other infection
types.
Figure 1 shows that during the 6-year study period, the average
hospital-wide HAI rate of the 121 hospitals decreased from 3.5 per
1000 patient-days in 2003 to 2.8 per 1000 patient-days in 2008
(P,0.0001). During this time, the proportion of A. baumannii
among all pathogens causing HAIs declined from 11.8% in 2003
to 9.4% in 2008 (P,0.0001) (data not shown). The infection rate
of A. baumannii decreased from 0.41 per 1000 patient-days in 2003
to 0.27 per 1000 patient-days in 2008 (P,0.0001). However, the
infection rate of CRAB doubled during the 6-year period, from
0.06 to 0.12 per 1000 patient-days (P,0.0001).
The median duration from admission to A. baumannii infection
was 23 days (IQR, 13–42) for patients with CRAB infections and
18 days (IQR, 10–33) for those with CSAB infection (P,0.0001).
Table 2 shows that the most common CSAB infections were
pneumonia (n=3174, 33%), bloodstream infection (n=2683,
28%), and urinary tract infection (n=2126, 22%) and that the
most common CRAB infections were pneumonia (n=1667, 39%),
urinary tract infection (n =1165, 27%), and bloodstream infection
(n=786, 18%). Among all infections caused by A. baumannii,
bloodstream infection was significantly less likely to be caused by
CRAB than surgical site infection (OR: 1.3; 95% CI: 1.1–1.5),
pneumonia (OR: 1.8, 95% CI: 1.6–2.0), urinary tract infection
(OR: 1.9; 95% CI: 1.7–2.1), and other infections (OR: 1.7; 95%
CI: 1.5–2.0).
Table 2 also shows that there was a significant increase in
annual CRABpAB, from 14.1% in 2003 to 46.3% in 2008
(P,0.0001). Figure 2 shows geographic differences in CRABpAB
(data was not shown for a region if the annual number of infections
was less than 20). In 2003, the regions with the highest and lowest
CRABpAB were the Taipei region and the central region,
respectively. During the six study years, the percentages of A.
baumannii infection caused by CRAB increased in all six regions.
Notable, there was a remarkable increase in the CRABpAB in the
central region, from 3.8% in 2003 to 61.8% in 2008, and the
central region became the region with highest CRABpAB in 2008.
The increase in the Taipei region was more modest, from 19.8%
in 2003 to 30.8% in 2008.
Association of hospital antimicrobial usage and CRABpAB
Table 3 shows the association between the annual CRABpAB
and annual hospital antimicrobial usage in the six geographic
regions from 2003 to 2008. During the 6-year study period, the
annual use of anti-pseudomonal cephalosporins, anti-pseudomonal
carbapenems, b-lactam-b-lactamase inhibitor combinations with
anti-pseudomonal effect, and anti-pseudomonal fluoroquinolones
increased from 16.4 to 24.7, 11.0 to 20.2, 12.1 to 18.7, and 32.1 to
47.9 DDDs per 1000 patient-days, respectively. However, the
annual use of aminoglycosides decreased from 90.0 to 44.0 DDDs
per 1000 patient-days.
Figure 3 shows scattergrams of annual CRABpAB and annual
consumption of each of the five classes antimicrobials stratified by
five geographic regions. The results indicate that the annual use of
anti-pseudomonal carbapenems was strongly correlated with the
increase of annual CRABpAB (r=0.86; P,0.0001). None of the
other classes of antimicrobial agents was significantly associated
with the increase in annual CRABpAB.
Discussion
Our study of A. baumannii HAIs in Taiwan indicated that the
CRABpAB increased from 14.1% in 2003 to 46.3% in 2008, and
that the incidence rates of HAIs caused by CRAB increased from
0.06 per 1000 patient-days in 2003 to 0.12 per 1000 patient-days
in 2008. The increase in CRABpAB was especially remarkable in
the central region of Taiwan, which had a 16-fold increase. Our
results also indicate that the increase of CRABpAB was strongly
associated with the increased use of anti-pseudomonal carbape-
nems, but not with antimicrobial agents of other classes.
Previous research has reported that the prevalence of carbape-
nem resistance among Acinetobacter species ranged from 6% to 52%
in Western countries and 2% to 26% in Asian/Pacific countries
other than Taiwan [5]. The results of the present study indicate
a higher burden of CRAB in Taiwan than other Asian countries.
This is a serious concern, because many prior studies have
reported that infection caused by CRAB was associated with
greater mortality and morbidity [6]. Only limited antibiotics are
available for treatment of CRAB infection [22,23].Therefore,
control of the spread of CRAB is a major medical problem.
Previous studies have indicated that risk factors for CRAB
acquisition were longer hospital stays, longer ICU stays, invasive
procedures, admission to a ward with a high density of patients
infected with CRAB, and previous exposure to antibiotics
(especially carbapenems) [8,11,13,24,25,26,27,28,29,30]. The
findings of the present study are similar. Although many of the
factors associated with CRAB infection are not modifiable, prior
exposure to carbapenems is a modifiable risk factor. Thus, we
suggest that more discretion be used in the administration of
carbapenems so as to control the transmission and spread of
CRAB.
Previous studies of CRAB typically used individual-level and
single center data to investigate the association between antibiotic
Figure 2. Proportions of CRAB among all A. baumannii at hospitals in six geographic regions of Taiwan.
doi:10.1371/journal.pone.0037788.g002
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investigated multiple centers or used aggregated population-level
data [8,10,13,24,26,27,28,29]. Studies using individual-level data
would neglect the indirect, and possibly significant, effects of the
antibiotics exposure of people who are near the index person
[10,11]. One population-level study only examined data collected
from 152 patients admitted at 11 hospitals [11]. Our present study
used nation-wide population-level data of 4315 patients with
CRAB infection from 121 hospitals. To our best knowledge, the
current study is the largest ecological study to investigate the
association between antibiotics exposure and acquisition of CRAB.
In addition, our results indicate that the increase of CRABpAB
occurred at all types of Taiwanese hospitals.
The major limitation of this study is that we observed
a population-level of hospital antimicrobial usage on CRABpAB,
but did not examine individual-level antimicrobial exposure data
simultaneously. We cannot establish a temporal relationship at
patient level. We therefore cannot make a definite causal
inference. However, because anti-pseudomonal carbapenems are
not effectively against CRAB, the increased consumption of anti-
pseudomonal carbapenems is more likely to be the cause of the
increase in CRABpAB. Moreover, we did not use molecular
typing to identify whether there were epidemics caused by CRAB
in the study hospitals or not. If epidemics did exist, some other
factors, such as problem of hygiene, would play a role in
contributing the increase of CRABpAB. However, the incidence
rates of A. baumannii HAIs and overall HAIs decreased while
CRAB HAIs increased during the study periods (figure 1). We
therefore considered that hygiene should not be a major factor
resulting in the increase of CRABpAB during our study period.
Several studies conducted during this period in Taiwan did
demonstrate that intra-hospital outbreaks and inter-hospital
spread of CRAB were present; and the CRAB strains responsible
for these outbreaks are similar in northern, central, and southern
Taiwan [31,32,33,34]. However, there were also some studies
demonstrating that even in the situation of outbreaks, prior
exposure to imipenem and/or meropenem remained an in-
dependently factor for subsequent acquirement of CRAB
[8,35,36]. In this way, even in the presence of outbreaks episodes,
selective pressure from antibiotic exposure would be still one of the
important factors leading to the increase of CRABpAB.
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Figure 3. Scattergrams of annual CRABpAB and annual
consumption of five classes of antimicrobial agents.
doi:10.1371/journal.pone.0037788.g003
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37788In conclusion, our multicenter, population-level study demon-
strated a high burden of CRAB and a strong association between
increased consumption of anti-pseudomonal carbapenems and
increase of CRABpAB in Taiwanese hospitals. We suggest that
restriction of anti-pseudomonal carbapenems may help to control
the further spread of CRAB.
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